A prospective, multicenter, randomised, double-blind, placebo-controlled, phase 3 study to compare the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe uncontrolled asthma and elevated eosinophil levels
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Masitinib (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AB Science
- 01 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2017 According to an AB Science media release, the first patient has been recruited in this trial.
- 31 Aug 2017 According to an AB Science media release, status changed from not yet recruiting to recruiting.